NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 14.89 percent. This is a 17.65 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $3.040 million which beat the analyst consensus estimate of $936.364 thousand by 224.66 percent. This is a 2.08 percent increase over sales of $2.978 million the same period last year.